Induction of apoptosis as a potential chemopreventive effect of dual cycloxygenase inhibitor, diclofenac, in early colon carcinogenesis

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 29, Issue 1, 2010, Pages 41-53

  Sanyal, Sankar Nath ^a   Kaur, Jasmeet ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Aberrant crypt foci; Apoptosis; Colon cancer; Diclofenac

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CYCLOOXYGENASE 2; DICLOFENAC;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; DRUG MECHANISM; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALIA; RATTUS; RODENTIA;

EID: 77952157424     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v29.i1.70     Document Type: Article

References (39)

1. Thun MJ, Henley SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic,pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266
2. Warner TD, Mitchell JA. Cycloxygenases: new forms, new inhibitors and lessons from the clinic. FASEB J.2004;18:790-804.
3. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Leo BA, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073
4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology.1994;107:1183-1188
5. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785-3789
6. Piazza GA, Rahm ALK, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, Ahnen DJ. Antineoplastic drugs sulin-dac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55:3110-3116
7. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfi de, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest.1995;96:491-503.
8. Figureras A, Capella D, Castel JM, Laporte JR. Spontaneous reporting of adverse drug reactions to nonsteroidal anti-infl ammatory drugs. Eur J Clin Pharmacol.1994;47:297-303.
9. Alam CAS, Seed MP, Willoughby DA. Angiostasis and vascular regression in chronic gramlomatous inflammation induced by diclofenac in combination with Hyaluronan. J Pharm Pharmacol. 1995;47:407-411
10. Harper D. A review of current clinical trials with HYAL CT-1101, HYALAT-2101 and HYALAV-2201. R Soc Med Round Table Ser. 1994;33:60-63
11. Seed MP, Brown JR, Freemantle CN, Papwethr JL, Colville-Nash PR, Willis D, Somville KW, Asculai S, Willoughby DA. The inhibitor of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res. 1997,57:1625-1629
12. Vane JR, Bakhle YS, Botting RM. Cycloxygenase 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
13. Vane JR, Botting RM. Anti-infl ammatory drugs and the mechanism of action. Infl amm Res. 1998;47:578-587
14. Williams JL, Borgo S, Hasan I, Castillo E, Traganes F, Rigs B. Nitric oxide-releasing non-steroidal antiinflammatory drugs (NSAIDs) alter the kinetic of human colon cancer cell lines more effectively than traditional NSAIDs. Implications for colon cancer chemoprevention. Cancer Res. 2001;61:3285-3289
15. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible Nitric Oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 2002;62:165-170
16. Mouille B, Robert V, Blachier F. Adaptive increase of ornithine production and decrease of ammonia metabolism in rat colonocytes and hyperproteic diet ingestion. Am J Physiol Gastrointest Liver Physiol.2004;287:G344-51.
17. Roediger WE, Truelove SC. Method of preparing isolated colonic epithelial cells (colonocytes) for metabolic studies. Gut. 1979;20:484-488
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
19. Kaltenbach JP, Kaltenbach MH, Lyons WB. Nigrosin as a dye for differentiating live and dead ascites cells. Exp Cell Res. 1958;15:112-117
20. Duke RC, Cohen JJ. Morphological and biochemical assays of apoptosis. Curr Protocol Immunol Suppl. 1992;3:17.1-16
21. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J. Mesengial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesengial proliferative nephritis.J Clin Invest. 1994;94:2105-2116
22. Schwartz LM, Obsorne BA. Cell death. Method Cell Biol. 1995;46:15-18
23. Yuan Y, Zhi-Qiang GE, Jing-Chuan L. Differentiation of apoptotic and necrotic cells in suspension cultures of Taxus cuspidate by the combined use of fluorescent dying and histochemical staining methods. Biotechnol Lett. 2002;24:71-76
24. Winter CA, Risley EA, Nuss GW. Carrageenan induced oedema in hind paw of the rat as an assay of anti-infl ammatory drugs. Proc Soc Exp Biol Med.1962;111:544-547
25. Samud AW, Asmawi MZ, Sharma JN, Yusof AP. Anti-infl ammatory activity of Crinum asiaticum plant and its effect on bradykinin-induced contractions on isolated uterus. Immunopharmacology. 1999;43:311-316
26. Wargovich MJ, Jimenez A, McKee K, Steele VE, Velaseo M, Woods J, Price R, Gray K, Kelloff GF. Efficacy of potential chemopreventive agents in rat colon aberrant crypt formation and progression.Carcinogenesis. 2000;21:1149-1155
27. Steele VE, Wargovich MJ, Pereira MA, Rao CV, Lubet RA, Reddy BS, Kellof GF. Comparison of the azoxymethane (AOM)-induced rat colon crypt assay with the rat colon tumor assay of cancer chemopreventive agents. Proc Am Assoc Cancer Res. 1999;40:A377.
28. Paulsen JE, Lobsg EM, Olstom HB, Knutoen H, Steffinsen I-L, Alexander J. Flat dysplastic aberrant crypt foci are related to tumorigenesis in the colon of azoxymethane treated rat. Cancer Res. 2005;65:121-129
29. Wargovich MJ, Chen CD, Harris C, Yan E, Velasco M. Inhibition of aberrant crypt growth by non-steroidal anti-infl ammatory agents in the rat colon. Int J Cancer. 1995;60:515-519
30. Battisini B, Botting R, Bakhle YS. COX-1 and COX-2: towards the development of more selective agents.Drug News and Prospect. 1994;7:501-512
31. Koyama H, Narisawa T, Kodama M, Ishikawa K, Kusaka H, Yamazaki Y, Koyama K. Potent effects of the prostaglandin synthesis inhibitor indomethacin on the cellular immune response in gastrointestinal patients. J Jpn Soc Cancer Ther. 1989;24:1027-1033
32. Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, Lin YS. GSK3β acts downstream of PP2A and the PI-3kinase-Akt pathway and upstream of caspase-2 in ceramide induced mitochondrial apoptosis. J Cell Sci. 2007;120:2935-2943
33. Simmons DL, Lu X, Bradshaw WS, Xie W. The dilemma of two cycloxygenases: identifying the roles of COX-1 and COX-2 in infl ammation and apoptosis. In: Vane JR, Botting J, Botting R, editors. Improved Non-steroidal anti-infl ammatory drugs: COX-2 enzyme inhibitors, Lancaster, UK: Kluwer Academic; 1996. p. 45-65.
34. Hofer M, Hoferoya Z, Pedorocko P, Mackova NO. Hematopoeisis-stimulating and antitumor effects of repeated administration of diclofenac in mice with transplanted fi brosarcoma cells. Physiol Res.2002;51:629-632
35. Crockart N, Radermacher K, Jordan B, Bandelet C, Cron GO, Gregoire V, Beghein N, Bonzin C, Feron O, Gallez B. Tumor radiosensitization by anti-infl ammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res. 2005;65:7911-7916
36. Falkowski M, Skogstad S, Shahzidi S, Smedsröd B, Sveinbjörnsson B. The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma.Anticancer Res. 2003;23(3B):2303-2308
37. Mignotte B, Vayssierre JL. Mitochondria and apoptosis. Eur J Biochem. 1998;252:1-15.
38. Choa M, Gwaka J, Parka S, Wonc J, Kimd DE, Yeaa S, Chab IJ, Kimc TK, Shinb JG, Oha S. Diclofenac attenuates Wnt/β-catenin signaling in colon cancer cells by activation of NF-xB. FEBS Letters 2005;579: 4213-4218
39. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol. 2002; 61(1):7-12.